1、Novo Nordisk A/S Novo Alle 1,2880 Bagsvrd,Denmark CVR no.24256790ANNUALREPORT2024Novo Nordisk employees Steve Piaget and Marie Ange Gahozo from our site in Kalundborg,Denmark,overseeing an active construction project.This project is part of our investment of more than DKK 80 billion in new active ph

2、armaceutical ingredient facilities.These significant expansions aim to scale up production of life-changing treatments,including GLP-1-based medicines,to benefit many more people living with serious chronic diseases.MANAGEMENT REPORT101 Consolidated financial statements102 Income statement and State

3、ment of comprehensive income103 Cash flow statement104 Balance sheet105 Equity statement106 Notes to the Consolidated financial statements138 Statements and auditors reports138 Statement by the Board of Directors and Executive Management139 Independent auditors report141 Independent auditors limited

4、 assurance report on Sustainability statement143 Additional information144 More information145 Product overview146 Financial statements of the parent company47 General information47 ESG performance49 Basis for preparation of the Sustainability statement50 Sustainability governance51 Interests and vi

5、ews of stakeholders52 Double materiality assessment54 Environment54 Climate change60 Resource use and circular economy64 Pollution65 Water67 Biodiversity and ecosystems69 EU Taxonomy71 Social71 Patient protection and quality of life80 Own workforce88 Workers in the value chain90 Governance 90 Busine

6、ss conduct95 Appendix Annual reviewSustainability statementFinancial statements and additional information4 Introducing Novo Nordisk5 Letter from the Chair and the CEO7 Key figures8 Purpose and strategy9 Value creation10 Strategic Aspirations 2025 progress11 Strategic Aspirations12 Purpose and susta